Skip to main content

Advertisement

Log in

Herb–Drug Interactions with St John’s Wort (Hypericum perforatum): an Update on Clinical Observations

  • Review Article
  • Theme: Natural Products as Therapeutic Modulators
  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

St John’s wort (SJW) extracts, prepared from the aerial parts of Hypericum perforatum, contain numerous pharmacologically active ingredients, including naphthodianthrones (e.g., hypericin and its derivatives), phloroglucinols derivatives (e.g., hyperforin, which inhibits the reuptake of a number of neurotransmitters, including serotonin), and flavonoids. Such extracts are widely used for the treatment of mild-to-moderate depression. As a monotherapy, SJW has an encouraging safety profile. However, relevant and, in some case, life-threatening interactions have been reported, particularly with drugs which are substrate of cytochrome P450 and/or P-glycoprotein. Well-documented SJW interactions include (1) reduced blood cyclosporin concentration, as suggested by multiple case reports as well as by clinical trials, (2) serotonin syndrome or lethargy when SJW was given with serotonin reuptake inhibitors, (3) unwanted pregnancies in women while using oral contraceptives and SJW, and (4) reduced plasma drug concentration of antiretroviral (e.g., indinavir, nevirapine) and anticancer (i.e., irinotecan, imatinib) drugs. Hyperforin, which is believed to contribute to the antidepressant action of St John’s wort, is also strongly suspected to be responsible of most of the described interactions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Blumenthal M, Ferrier GKL, Cavaliere C. Total sales of herbal supplements in United States show steady growth. Herbal Gram. 2006;71:64–6.

    Google Scholar 

  2. Bent S. Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center. J Gen Intern Med. 2008;23:854–9.

    Article  PubMed  Google Scholar 

  3. Izzo AA. Herb–drug interactions: an overview of the clinical evidence. Fundam Clin Pharmacol. 2005;19:1–16.

    Article  PubMed  CAS  Google Scholar 

  4. De Smet PA. Clinical risk management of herb–drug interactions. Br J Clin Pharmacol. 2007;63:258–67.

    Article  PubMed  Google Scholar 

  5. Izzo AA. Drug interactions with St. John’s Wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther. 2004;42:139–48.

    PubMed  CAS  Google Scholar 

  6. Zhou SF, Lai X. An update on clinical drug interactions with the herbal antidepressant St. John’s wort. Curr Drug Metab. 2008;9:394–409.

    Article  PubMed  CAS  Google Scholar 

  7. Kober M, Pohl K, Efferth T. Molecular mechanisms underlying St. John’s wort drug interactions. Curr Drug Metab. 2008;9:1027–37.

    Article  PubMed  CAS  Google Scholar 

  8. Di YM, Li CG, Xue CC, Zhou SF. Clinical drugs that interact with St. John’s wort and implication in drug development. Curr Pharm Des. 2008;14:1723–42.

    Article  PubMed  CAS  Google Scholar 

  9. Linde K, Berner M, Egger M, Mulrow C. St John’s wort for depression: meta-analysis of randomised controlled trials. Br J Psychiatry. 2005;186:99–107.

    Article  PubMed  Google Scholar 

  10. Clement K, Covertson CR, Johnson MJ, Dearing K. St. John’s wort and the treatment of mild to moderate depression: a systematic review. Holist Nurs Pract. 2006;20:197–203.

    PubMed  Google Scholar 

  11. Linde K, Berner MM, Kriston L. St John’s wort for major depression. Cochrane Database Syst Rev. 2008;CD000448.

  12. Di Carlo G, Borrelli F, Ernst E, Izzo AA. St John’s wort: prozac from the plant kingdom. Trends Pharmacol Sci. 2001;22:292–7.

    Article  PubMed  Google Scholar 

  13. Capasso F, Gaginella TS, Grandolini G, Izzo AA. Phytotherapy. A quick reference to herbal medicine. Berlin: Springer; 2003.

    Google Scholar 

  14. Whitten DL, Myers SP, Hawrelak JA, Wohlmuth H. The effect of St John’s wort extracts on CYP3A: a systematic review of prospective clinical trials. Br J Clin Pharmacol. 2006;62:512–26.

    Article  PubMed  CAS  Google Scholar 

  15. Trepanier LA. Cytochrome P450 and its role in veterinary drug interactions. Vet Clin North Am Small Anim Pract. 2006;36:975–85.

    Article  PubMed  Google Scholar 

  16. Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfield F, et al. Clinical assessment of CYP2D6-mediated herb–drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John’s wort, and Echinacea. Mol Nutr Food Res. 2008;52:755–63.

    Article  PubMed  CAS  Google Scholar 

  17. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, et al. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John’s wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging. 2005;22:525–39.

    Article  PubMed  CAS  Google Scholar 

  18. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, et al. Cytochrome P450 phenotypic ratios for predicting herb–drug interactions in humans. Clin Pharmacol Ther. 2002;72:276–87.

    Article  PubMed  CAS  Google Scholar 

  19. Markowitz JS, DeVane CL, Boulton DW, Carson SW, Nahas Z, Risch SC. Effect of St. John’s wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci. 2000;66:PL133–9.

    Article  PubMed  CAS  Google Scholar 

  20. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS, et al. Effect of St John’s wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA. 2003;290:1500–4.

    Article  PubMed  CAS  Google Scholar 

  21. Arold G, Donath F, Maurer A, Diefenbach K, Bauer S, Henneicke-von Zepelin HH, et al. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John’s wort extract. Planta Med. 2005;71:331–7.

    Article  PubMed  CAS  Google Scholar 

  22. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John’s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther. 2001;70:317–26.

    PubMed  CAS  Google Scholar 

  23. Wang LS, Zhu B, Abd El-Aty AM, Zhou G, Li Z, Wu J, et al. The influence of St John’s Wort on CYP2C19 activity with respect to genotype. J Clin Pharmacol. 2004;44:577–81.

    Article  PubMed  CAS  Google Scholar 

  24. Wenk M, Todesco L, Krähenbühl S. Effect of St John’s wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol. 2004;57:495–9.

    Article  PubMed  CAS  Google Scholar 

  25. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St John’s wort in healthy subjects. Clin Pharmacol Ther. 2003;73:41–50.

    Article  PubMed  CAS  Google Scholar 

  26. Roby CA, Dryer DA, Burstein AH. St. John’s wort: effect on CYP2D6 activity using dextromethorphan–dextrorphan ratios. J Clin Psychopharmacol. 2001;21:530–2.

    Article  PubMed  CAS  Google Scholar 

  27. Xie R, Tan LH, Polasek EC, Hong C, Teillol-Foo M, Gordi T, et al. CYP3A and P-glycoprotein activity induction with St. John’s Wort in healthy volunteers from 6 ethnic populations. J Clin Pharmacol. 2005;45:352–6.

    Article  PubMed  CAS  Google Scholar 

  28. Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, et al. The interaction between St John’s wort and an oral contraceptive. Clin Pharmacol Ther. 2003;74:525–35.

    Article  PubMed  CAS  Google Scholar 

  29. Imai H, Kotegawa T, Tsutsumi K, Morimoto T, Eshima N, Nakano S, et al. The recovery time-course of CYP3A after induction by St John’s wort administration. Br J Clin Pharmacol. 2008;65:701–7.

    Article  PubMed  Google Scholar 

  30. Wang LS, Zhou G, Zhu B, Wu J, Wang JG, Abd El-Aty AM, et al. St John’s wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther. 2004;75:191–7.

    Article  PubMed  CAS  Google Scholar 

  31. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, et al. St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA. 2000;97:7500–2.

    Article  PubMed  CAS  Google Scholar 

  32. Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica. 2008;38:802–32.

    Article  PubMed  CAS  Google Scholar 

  33. Perloff MD, von Moltke LL, Störmer E, Shader RI, Greenblatt DJ. Saint John’s wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol. 2001;134:1601–8.

    Article  PubMed  CAS  Google Scholar 

  34. Hennessy M, Kelleher D, Spiers JP, Barry M, Kavanagh P, Back D, et al. St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol. 2002;53:75–82.

    Article  PubMed  CAS  Google Scholar 

  35. Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort (Hypericum perforatum). Clin Pharmacol Ther. 1999;66:338–45.

    Article  PubMed  CAS  Google Scholar 

  36. Mueller SC, Uehleke B, Woehling H, Petzsch M, Majcher-Peszynska J, Hehl EM, et al. Effect of St John’s wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther. 2004;75:546–57.

    Article  PubMed  CAS  Google Scholar 

  37. Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, et al. St John’s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther. 2000;68:598–604.

    Article  PubMed  Google Scholar 

  38. Schwarz UI, Hanso H, Oertel R, Miehlke S, Kuhlisch E, Glaeser H, et al. Induction of intestinal P-glycoprotein by St John’s wort reduces the oral bioavailability of talinolol. Clin Pharmacol Ther. 2007;81:669–78.

    Article  PubMed  CAS  Google Scholar 

  39. Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD. Effect of St John’s wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther. 2002;71:414–20.

    Article  PubMed  CAS  Google Scholar 

  40. Rengelshausen J, Banfield M, Riedel KD, Burhenne J, Weiss J, Thomsen T, et al. Opposite effects of short-term and long-term St John’s wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther. 2005;78:25–33.

    Article  PubMed  CAS  Google Scholar 

  41. Mai I, Bauer S, Perloff ES, Johne A, Uehleke B, Frank B, et al. Hyperforin content determines the magnitude of the St John’s wort–cyclosporine drug interaction. Clin Pharmacol Ther. 2004;76:330–40.

    Article  PubMed  CAS  Google Scholar 

  42. Mueller SC, Majcher-Peszynska J, Uehleke B, Klammt S, Mundkowski RG, Miekisch W, et al. The extent of induction of CYP3A by St. John’s wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol. 2006;62:29–36.

    Article  PubMed  CAS  Google Scholar 

  43. Mueller SC, Majcher-Peszynska J, Mundkowski RG, Uehleke B, Klammt S, Sievers H, et al. No clinically relevant CYP3A induction after St. John’s wort with low hyperforin content in healthy volunteers. Eur J Clin Pharmacol. 2009;65:81–7.

    Article  PubMed  CAS  Google Scholar 

  44. L’homme RF, Dijkema T, van der Ven AJ, Burger DM. Brief report: enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women. J Acquir Immune Defic Syndr. 2006;43:193–6.

    Article  PubMed  CAS  Google Scholar 

  45. Will-Shahab L, Bauer S, Kunter U, Roots I, Brattström A. St John’s wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive. Eur J Clin Pharmacol. 2009;65:287–94.

    Article  PubMed  Google Scholar 

  46. Zhou SF, Zhou ZW, Li CG, Chen X, Yu X, Xue CC, et al. Identification of drugs that interact with herbs in drug development. Drug Discov Today. 2007;12:664–73.

    Article  PubMed  CAS  Google Scholar 

  47. Bon S, Hartmann K, Kubn M. Johanniskraut: ein enzyminduktor? Schweitzer Apothekerzeitung. 1999;16:535–6.

    Google Scholar 

  48. Breidenbach T, Kliem V, Burg M, Radermacher J, Hoffmann MW, Klempnauer J. Profound drop of cyclosporin A whole blood trough levels caused by St. John’s wort (Hypericum perforatum). Transplantation. 2000;69:2229–30.

    Article  PubMed  CAS  Google Scholar 

  49. Breidenbach T, Hoffmann MW, Becker T, Schlitt H, Klempnauer J. Drug interaction of St John’s wort with cyclosporin. Lancet. 2000;355:1912.

    Article  PubMed  CAS  Google Scholar 

  50. Roots I, Johne A, Mauer A, et al. Arzneimittel interaktionen von hypericum-extract. Proc Germ Soc Pharmacol. 2000; Berlin.

  51. Rey JM, Walter G. Hypericum perforatum (St John’s wort) in depression: pest or blessing? Med J Aust. 1998;169:583–6.

    PubMed  CAS  Google Scholar 

  52. Ruschitzka F, Meier PJ, Turina M, Lüscher TF, Noll G. Acute heart transplant rejection due to Saint John’s wort. Lancet. 2000;355:548–9.

    Article  PubMed  CAS  Google Scholar 

  53. Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. Drug interaction between St. John’s wort and cyclosporine. Ann Pharmacother. 2000;34:1013–6.

    Article  PubMed  CAS  Google Scholar 

  54. Mai I, Krüger H, Budde K, Johne A, Brockmöller J, Neumayer HH, et al. Hazardous pharmacokinetic interaction of Saint John’s wort (Hypericum perforatum) with the immunosuppressant cyclosporin. Int J Clin Pharmacol Ther. 2000;38:500–2.

    PubMed  CAS  Google Scholar 

  55. Karliova M, Treichel U, Malagò M, Frilling A, Gerken G, Broelsch CE. Interaction of Hypericum perforatum (St. John’s wort) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol. 2000;33:853–5.

    Article  PubMed  CAS  Google Scholar 

  56. Mandelbaum A, Pertzborn F, Martin-Facklam M, Wiesel M. Unexplained decrease of cyclosporin trough levels in a compliant renal transplant patient. Nephrol Dial Transplant. 2000;15:1473–4.

    Article  PubMed  CAS  Google Scholar 

  57. Turton-Weeks SM, Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. St John’s wort: a hidden risk for transplant patients. Prog Transplant. 2001;11:116–20.

    PubMed  CAS  Google Scholar 

  58. Ahmed SM, Banner NR, Dubrey SW. Low cyclosporin-A level due to Saint-John’s-wort in heart transplant patients. J Heart Lung Transplant. 2001;20:795.

    Article  PubMed  CAS  Google Scholar 

  59. Beer AM, Ostermann T. St. John’s wort: interaction with cyclosporine increases risk of rejection for the kidney transplant and raises daily cost of medication. Med Klin (Munich). 2001;96:480–3.

    Article  CAS  Google Scholar 

  60. Moschella C, Jaber BL. Interaction between cyclosporine and Hypericum perforatum (St. John’s wort) after organ transplantation. Am J Kidney Dis. 2001;38:1105–7.

    Article  PubMed  CAS  Google Scholar 

  61. Alscher DM, Klotz U. Drug interaction of herbal tea containing St. John’s wort with cyclosporine. Transpl Int. 2003;16:543–4.

    Article  PubMed  Google Scholar 

  62. Bolley R, Zülke C, Kammerl M, Fischereder M, Krämer BK. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John’s wort. Transplantation. 2002;73:1009.

    Article  PubMed  Google Scholar 

  63. Hebert MF, Park JM, Chen YL, Akhtar S, Larson AM. Effects of St. John’s wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol. 2004;44:89–94.

    Article  PubMed  CAS  Google Scholar 

  64. Mai I, Störmer E, Bauer S, Krüger H, Budde K, Roots I. Impact of St John’s wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant. 2003;18:819–22.

    Article  PubMed  CAS  Google Scholar 

  65. Saraga M, Zullino DF. St. John’s wort, corticosteroids, cocaine, alcohol and a first manic episode. Praxis (Bern 1994). 2005;94:987–9.

    Article  CAS  Google Scholar 

  66. Bell EC, Ravis WR, Chan HM, Lin YJ. Lack of pharmacokinetic interaction between St. John’s wort and prednisone. Ann Pharmacother. 2007;41:1819–24.

    Article  PubMed  CAS  Google Scholar 

  67. Yue QY, Bergquist C, Gerdén B. Safety of St John’s wort (Hypericum perforatum). Lancet. 2000;355:576–7.

    Article  PubMed  CAS  Google Scholar 

  68. Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J. Interaction of St John’s wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol. 2003;56:683–90.

    Article  PubMed  CAS  Google Scholar 

  69. Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL. Interaction of St. John’s wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception. 2005;71:402–8.

    Article  PubMed  CAS  Google Scholar 

  70. Schwarz UI, Büschel B, Kirch W. Unwanted pregnancy on self-medication with St John’s wort despite hormonal contraception. Br J Clin Pharmacol. 2003;55:112–3.

    Article  PubMed  Google Scholar 

  71. Skolnick JL, Stoler BS, Katz DB, Anderson WH. Rifampin, oral contraceptives, and pregnancy. JAMA. 1976;236:1382.

    Article  PubMed  CAS  Google Scholar 

  72. Lazovic G, Radivojevic U, Marinkovic J. Tibolone: the way to beat many a postmenopausal ailments. Expert Opin Pharmacother. 2008;9:1039–47.

    Article  PubMed  CAS  Google Scholar 

  73. Etogo-Asse F, Boemer F, Sempoux C, Geubel A. Acute hepatitis with prolonged cholestasis and disappearance of interlobular bile ducts following tibolone and Hypericum perforatum (St. John’s wort). Case of drug interaction? Acta Gastroenterol Belg. 2008;71:36–8.

    PubMed  CAS  Google Scholar 

  74. Huang SM, Lesko LJ, Williams RL. Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues. J Clin Pharmacol. 1999;39:1006–14.

    Article  PubMed  CAS  Google Scholar 

  75. O’Reilly RA. Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther. 1974;16:348–54.

    PubMed  Google Scholar 

  76. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, et al. Effect of St John’s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol. 2004;57:592–9.

    Article  PubMed  CAS  Google Scholar 

  77. Donath F, Roots I, Langheinrich M, et al. Interaction of St John’s wort extract with phenprocoumon. Eur J Clin Pharmacol. 1999;55:A22.

    Google Scholar 

  78. Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, et al. Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther. 2001;70:518–24.

    Article  PubMed  CAS  Google Scholar 

  79. Andrén L, Andreasson A, Eggertsen R. Interaction between a commercially available St. John’s wort product (Movina) and atorvastatin in patients with hypercholesterolemia. Eur J Clin Pharmacol. 2007;63:913–6.

    Article  PubMed  Google Scholar 

  80. Wang XD, Li JL, Su QB, Guan S, Chen J, Du J, et al. Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John’s wort-induced activity of cytochrome P450 3A4 enzyme. Br J Clin Pharmacol. 2009;67:255–61.

    Article  PubMed  CAS  Google Scholar 

  81. Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Lennernäs H. St John’s wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clin Pharmacol Ther. 2004;75:298–309.

    Article  PubMed  CAS  Google Scholar 

  82. Tardif JC. Ivabradine: I(f) inhibition in the management of stable angina pectoris and other cardiovascular diseases. Drugs Today (Barc). 2008;44:171–81.

    Article  CAS  Google Scholar 

  83. Portolés A, Terleira A, Calvo A, Martínez I, Resplandy G. Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. J Clin Pharmacol. 2006;46:1188–94.

    Article  PubMed  CAS  Google Scholar 

  84. van den Bout-van den Beukel CJ, Koopmans PP, van der Ven AJ, De Smet PA, Burger DM. Possible drug–metabolism interactions of medicinal herbs with antiretroviral agents. Drug Metab Rev. 2006;38:477–514.

    Article  PubMed  CAS  Google Scholar 

  85. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John’s wort. Lancet. 2000;355:547–8.

    Article  PubMed  CAS  Google Scholar 

  86. Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, et al. Herb–drug interactions: a literature review. Drugs. 2005;65:1239–82.

    Article  PubMed  CAS  Google Scholar 

  87. de Maat MM, Hoetelmans RM, Math t RA, van Gorp EC, Meenhorst PL, Mulder JW, et al. Drug interaction between St John’s wort and nevirapine. AIDS. 2001;15:420–1.

    Article  PubMed  Google Scholar 

  88. Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos. 1999;27:1488–95.

    PubMed  CAS  Google Scholar 

  89. Meijerman I, Beijnen JH, Schellens JH. Herb–drug interactions in oncology: focus on mechanisms of induction. Oncologist. 2006;11:742–52.

    Article  PubMed  CAS  Google Scholar 

  90. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. Effects of St. John’s wort on irinotecan metabolism. J Natl Cancer Inst. 2002;94:1247–9.

    PubMed  CAS  Google Scholar 

  91. Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ. Effect of St John’s wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther. 2004;76:323–9.

    Article  PubMed  CAS  Google Scholar 

  92. Smith P, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ. The influence of St. John’s wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy. 2004;24:1508–14.

    Article  PubMed  CAS  Google Scholar 

  93. Kales A. Quazepam: hypnotic efficacy and side effects. Pharmacotherapy. 1990;10:1–10.

    PubMed  CAS  Google Scholar 

  94. Kawaguchi A, Ohmori M, Tsuruoka S, Nishiki K, Harada K, Miyamori I, et al. Drug interaction between St John’s wort and quazepam. Br J Clin Pharmacol. 2004;58:403–10.

    Article  PubMed  CAS  Google Scholar 

  95. Dannawi M. Possible serotonin syndrome after combination of buspirone and St John’s wort. J Psychopharmacol. 2002;16:401.

    Article  PubMed  Google Scholar 

  96. Spinella M, Eaton LA. Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury. Brain Inj. 2002;16:359–67.

    Article  PubMed  Google Scholar 

  97. Lantz MS, Buchalter E, Giambanco V. St. John’s wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol. 1999;12:7–10.

    Article  PubMed  CAS  Google Scholar 

  98. Gordon JB. SSRIs and St John’s wort: possible toxicity? Am Fam Phys. 1998;57:950.

    CAS  Google Scholar 

  99. Prost N, Tichadou L, Rodor F, Nguyen N, David JM, Jean-Pastor MJ. St. Johns wort–venlafaxine interaction. Presse Med. 2000;29:1285–6.

    PubMed  CAS  Google Scholar 

  100. Barbenel DM, Yusufi B, O’Shea D, Bench CJ. Mania in a patient receiving testosterone replacement postorchidectomy taking St John’s wort and sertraline. J Psychopharmacol. 2000;14:84–6.

    Article  PubMed  CAS  Google Scholar 

  101. Fugh-Berman A, Ernst E. Herb–drug interactions: review and assessment of report reliability. Br J Clin Pharmacol. 2001;52:587–95.

    Article  PubMed  CAS  Google Scholar 

  102. Johne A, Schmider J, Brockmöller J, Stadelmann AM, Störmer E, Bauer S, et al. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John’s wort (Hypericum perforatum). J Clin Psychopharmacol. 2002;22:46–54.

    Article  PubMed  CAS  Google Scholar 

  103. Burstein AH, Horton RL, Dunn T, Alfaro RM, Piscitelli SC, Theodore W. Lack of effect of St John’s wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther. 2000;68:605–12.

    Article  PubMed  CAS  Google Scholar 

  104. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, et al. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol. 1994;47:1969–79.

    Article  PubMed  CAS  Google Scholar 

  105. Johne A, Perloff ES, Bauer S, Schmider J, Mai I, Brockmöller J, et al. Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers. Eur J Clin Pharmacol. 2004;60:617–22.

    Article  PubMed  CAS  Google Scholar 

  106. Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA. 2001;286:208–16.

    Article  PubMed  CAS  Google Scholar 

  107. Crowe S, McKeating K. Delayed emergence and St. John’s wort. Anesthesiology. 2002;96:1025–7.

    Article  PubMed  Google Scholar 

  108. Irefin S, Sprung J. A possible cause of cardiovascular collapse during anesthesia: long-term use of St. John’s wort. J Clin Anesth. 2000;12:498–9.

    Article  PubMed  CAS  Google Scholar 

  109. Eich-Höchli D, Oppliger R, Golay KP, Baumann P, Eap CB. Methadone maintenance treatment and St. John’s wort—a case report. Pharmacopsychiatry. 2003;36:35–7.

    Article  PubMed  Google Scholar 

  110. Wilkes S. The use of bupropion SR in cigarette smoking cessation. Int J Chron Obstruct Pulmon Dis. 2008;3:45–53.

    PubMed  CAS  Google Scholar 

  111. Milton JC, Abdulla A. Prolonged oro-facial dystonia in a 58 year old female following therapy with bupropion and St John’s wort. Br J Clin Pharmacol. 2007;64:717–8.

    Article  PubMed  Google Scholar 

  112. Bryant SM, Kolodchak J. Serotonin syndrome resulting from an herbal detox cocktail. Am J Emerg Med. 2004;22:625–6.

    Article  PubMed  Google Scholar 

  113. Hansel TT, Tennant RC, Tan AJ, Higgins LA, Neighbour H, Erin EM, et al. Theophylline: mechanism of action and use in asthma and chronic obstructive pulmonary disease. Drugs Today (Barc). 2004;40:55–69.

    Article  CAS  Google Scholar 

  114. Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St. John’s wort and theophylline. Ann Pharmacother. 1999;33:502.

    Article  PubMed  CAS  Google Scholar 

  115. Morimoto T, Kotegawa T, Tsutsumi K, Ohtani Y, Imai H, Nakano S. Effect of St. John’s wort on the pharmacokinetics of theophylline in healthy volunteers. J Clin Pharmacol. 2004;44:95–101.

    Article  PubMed  CAS  Google Scholar 

  116. Xu H, Williams KM, Liauw WS, Murray M, Day RO, McLachlan AJ. Effects of St John’s wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. Br J Pharmacol. 2008;153:1579–86.

    Article  PubMed  CAS  Google Scholar 

  117. Brüggemann RJ, Donnelly JP, Aarnoutse RE, Warris A, Blijlevens NM, Mouton JW, et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit. 2008;30:403–11.

    Article  PubMed  Google Scholar 

  118. Sandrini G, Perrotta A, Nappi G. Eletriptan: a review and new perspectives. Expert Rev Neurother. 2006;6:1413–21.

    Article  PubMed  CAS  Google Scholar 

  119. Bonetto N, Santelli L, Battistin L, Cagnin A. Serotonin syndrome and rhabdomyolysis induced by concomitant use of triptans, fluoxetine and hypericum. Cephalalgia. 2007;27:1421–3.

    Article  PubMed  CAS  Google Scholar 

  120. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64:935–51.

    Article  PubMed  CAS  Google Scholar 

  121. Baker DE. Loperamide: a pharmacological review. Rev Gastroenterol Disord. 2007;7:S11–8.

    PubMed  Google Scholar 

  122. Khawaja IS, Marotta RF, Lippmann S. Herbal medicines as a factor in delirium. Psychiatr Serv. 1999;50:969–70.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Francesca Borrelli.

Additional information

Guest Editor: Marilyn E. Morris

Rights and permissions

Reprints and permissions

About this article

Cite this article

Borrelli, F., Izzo, A.A. Herb–Drug Interactions with St John’s Wort (Hypericum perforatum): an Update on Clinical Observations. AAPS J 11, 710–727 (2009). https://doi.org/10.1208/s12248-009-9146-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12248-009-9146-8

Key words

Navigation